Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Peintinger, H. Kuerer, K. Anderson, J. Boughey, F. Meric-Bernstam, S. Singletary, K. Hunt, G. Whitman, T. Stephens, A. Buzdar, Marjorie Green, W. Symmans (2006)Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy
Annals of Surgical Oncology, 13
L. Gianni, T. Pieńkowski, Y. Im, L. Roman, L. Tseng, Mei-Ching Liu, A. Lluch, E. Starosławska, J. Haba-Rodríguez, S. Im, J. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, T. Szado, J. Ratnayake, G. Ross, P. Valagussa (2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
The Lancet. Oncology, 13 1
R. Haque, Syed Ahmed, G. Inzhakova, Jiaxiao Shi, C. Avila, J. Polikoff, L. Bernstein, S. Enger, M. Press (2012)Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades
Cancer Epidemiology, Biomarkers & Prevention, 21
A. Chagpar, L. Middleton, A. Sahin, P. Dempsey, A. Buzdar, Attiqa Mirza, F. Ames, G. Babiera, B. Feig, K. Hunt, H. Kuerer, F. Meric-Bernstam, M. Ross, S. Singletary (2006)Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy
Annals of Surgery, 243
A. Prat, A. Lluch, J. Albanell, William Barry, Chunxia Fan, J. Chacón, Joel Parker, L. Calvo, A. Plazaola, Á. Arcusa, M. Seguí-Palmer, O. Burgués, N. Ribelles, Á. Rodríguez-Lescure, Á. Guerrero, M. Ruiz-Borrego, B. Munárriz, José López, B. Adamo, M. Cheang, Yufeng Li, Zhiyuan Hu, M. Gulley, M. Vidal, B. Pitcher, M-L Liu, M. Citron, M. Ellis, E. Mardis, T. Vickery, C. Hudis, Eric Winer, L. Carey, R. Caballero, E. Carrasco, Miguel Martin, C. Perou, E. Alba (2014)Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, 111
G. Minckwitz, M. Untch, J. Blohmer, S. Costa, H. Eidtmann, P. Fasching, B. Gerber, W. Eiermann, J. Hilfrich, J. Huober, C. Jackisch, M. Kaufmann, G. Konecny, C. Denkert, V. Nekljudova, K. Mehta, S. Loibl (2012)Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
J. Parker, Michael Mullins, M. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, Xiaping He, Zhiyuan Hu, J. Quackenbush, I. Stijleman, J. Palazzo, J. Marron, A. Nobel, E. Mardis, T. Nielsen, M. Ellis, C. Perou, P. Bernard (2009)Supervised risk predictor of breast cancer based on intrinsic subtypes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
J. Hage, C. Velde, J. Julien, M. Tubiana-Hulin, Cecile Vandervelden, L. Duchateau (2001)Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 22
A. Schneeweiss, S. Chia, T. Hickish, Vernon Harvey, A. Eniu, R. Hegg, C. Tausch, J. Seo, Y. Tsai, J. Ratnayake, V. Mcnally, G. Ross, J. Cortés (2013)Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Annals of oncology : official journal of the European Society for Medical Oncology, 24 9
G. Cheng, A. Alavi (2012)The Value of 18F-FDG PET/CT in the Assessment of Cardiac Malignancy Remains to Be Defined
The Journal of Nuclear Medicine, 53
D. Krug, S. Loibl (2018)Neoadjuvant chemotherapy for early breast cancer.
The Lancet. Oncology, 19 3
J. Baselga, I. Bradbury, H. Eidtmann, S. Cosimo, E. Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Dooren, G. Aktan, A. Goldhirsch, Tsai-Wang Chang, Z. Horváth, M. Coccia-Portugal, J. Dômont, L. Tseng, G. Kunz, J. Sohn, V. Semiglazov, G. Lerzo, M. Pálácova, V. Probachai, L. Pusztai, M. Untch, R. Gelber, M. Piccart-Gebhart (2012)Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
The Lancet, 379
H. Bear, S. Anderson, Roy Smith, C. Geyer, E. Mamounas, B. Fisher, A. Brown, A. Robidoux, R. Margolese, M. Kahlenberg, S. Paik, A. Soran, D. Wickerham, N. Wolmark (2006)Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 13
J. Huober, G. Minckwitz, C. Denkert, H. Tesch, E. Weiss, D. Zahm, A. Belau, F. Khandan, M. Hauschild, C. Thomssen, B. Högel, S. Darb-Esfahani, K. Mehta, S. Loibl (2010)Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Breast Cancer Research and Treatment, 124
Ying Yuan, Xiao-song Chen, Shiyuan Liu, K. Shen (2010)Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis.
AJR. American journal of roentgenology, 195 1
P. Rastogi, S. Anderson, H. Bear, C. Geyer, M. Kahlenberg, A. Robidoux, R. Margolese, J. Hoehn, V. Vogel, S. Dakhil, D. Tamkus, K. King, E. Pajon, Mary Wright, J. Robert, S. Paik, E. Mamounas, N. Wolmark (2008)Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 5
D. Segara, I. Krop, J. Garber, E. Winer, L. Harris, J. Bellon, R. Birdwell, S. Lester, S. Lipsitz, J. Iglehart, M. Golshan (2007)Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?
Journal of Surgical Oncology, 96
G. Minckwitz, H. Eidtmann, M. Rezai, P. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, R. Kreienberg, C. Solbach, B. Gerber, C. Jackisch, G. Kunz, J. Blohmer, J. Huober, M. Hauschild, T. Fehm, B. Müller, C. Denkert, S. Loibl, V. Nekljudova, M. Untch (2012)Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
The New England journal of medicine, 366 4
C. Fiorentino, A. Berruti, A. Bottini, M. Bodini, M. Brizzi, A. Brunelli, Ugo Marini, G. Allevi, S. Aguggini, Angela Tira, P. Alquati, L. Olivetti, L. Dogliotti (2001)Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease
Breast Cancer Research and Treatment, 69
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S. Swain, Tatiana Prowell, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Minckwitz (2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
The Lancet, 384
(2014)Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer : Use as an Endpoint to Support Accelerated Approval
K. Hwang, Jung-Woo Woo, Heechul Shin, Han Kim, S. Ahn, H. Moon, W. Han, I. Park, D. Noh (2012)Prognostic influence of BCL2 expression in breast cancer
International Journal of Cancer, 131
M. Ellis, Y. Tao, Jingqin Luo, R. A’Hern, D. Evans, A. Bhatnagar, Hilary Ross, Alexander Kameke, W. Miller, I. Smith, W. Eiermann, M. Dowsett (2008)Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
JNCI Journal of the National Cancer Institute, 100
Breast cancer is a heterogeneous disease, and the different biological subtypes have different prognostic impacts. Neoadjuvant trials have recently become popular as they offer several advantages compared to traditional adjuvant trials. Studies have shown that patients who achieve pathological complete response (pCR) after neoadjuvant treatment have a better long-term outcome. Consequently, increasing the rate of pCR became the end point of neoadjuvant trials with the expectation of translation into improved survival. However, the definition of pCR has lacked uniformity, and the prognostic impact of achievement of pCR on survival in different breast cancer subtypes is uncertain. In this review, we present the controversies associated with the use of pCR as an end point in neoadjuvant trials.
Breast Cancer: Basic and Clinical Research – SAGE
Published: Jul 25, 2016
Keywords: pathological complete response; neoadjuvant; breast cancer
Access the full text.
Sign up today, get DeepDyve free for 14 days.